oa Professional Nursing Today - TB Alliance enters into collaboration with sanofi-aventis to fight tuberculosis
AstraZeneca and Nomura Phase4 Ventures announce creation of new company "Albireo" : industry news

Volume 12, Issue 5
  • ISSN : 1607-6672



The Global Alliance for TB Drug Development (TB Alliance) and sanofi-aventis announced today that they have entered into a collaboration agreement to accelerate the discovery, development and clinical use of drugs against tuberculosis (TB). The TB Alliance is a not-for-profit, product development partnership, whose goal is the development of new TB drugs.

AstraZeneca and Nomura Phase4 Ventures have announced the signing of a deal to form Albireo, a biotechnology company focused on developing new treatments for gastrointestinal (GI) disorders. The spinout is a result of AstraZeneca's previously announced strategic decision to concentrate on Nexiam and internal GI research focussed on Gastroesophageal Reflux Disease (GORD).

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error